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ABSTRACT
Better characterization of binding sites in proteins
and the ability to accurately predict their location
and energetic properties are major challenges
which, if addressed, would have many valuable
practical applications. Unfortunately, reliable
benchmark datasets of binding sites in proteins
are still sorely lacking. Here, we present LigASite
(‘LIGand Attachment SITE’), a gold-standard dataset
of binding sites in 550 proteins of known structures.
LigASite consists exclusively of biologically relevant
binding sites in proteins for which at least one apo-
and one holo-structure are available. In defining the
binding sites for each protein, information from all
holo-structures is combined, considering in each
case the quaternary structure defined by the PQS
server. LigASite is built using simple criteria and is
automatically updated as new structures become
available in the PDB, thereby guaranteeing optimal
data coverage over time. Both a redundant and
a culled non-redundant version of the dataset is
available at http://www.scmbb.ulb.ac.be/Users/
benoit/LigASite. The website interface allows users
to search the dataset by PDB identifiers, ligand
identifiers, protein names or sequence, and to look
for structural matches as defined by the CATH
homologous superfamilies. The datasets can be
downloaded from the website as Schema-validated
XML files or comma-separated flat files.
INTRODUCTION
An increasing number of proteins with unknown function
have their 3D structure solved at high resolution (1).
This situation, largely due to structural genomics
initiatives (2), has been stimulating the development of
automated structure-based function prediction methods
(3). Knowledge of residues important for function and—
more particularly—for binding, can help automated
prediction of function in diﬀerent ways. The properties
of a binding site such as its shape, atomic group or amino
acid composition can provide clues on the ligand that may
bind to it. Also, having information on functionally
important regions in similar proteins can reﬁne the process
of annotation transfer between homologues (4).
Several methods for predicting the location of binding
sites in protein structures are available and many more are
currently being developed (5–7). Most of these methods
need examples of known binding sites in order to derive
features, which can subsequently be used to distinguish
between true binding sites and sites not involved in
binding. The adequate use of such methods requires the
availability of valid benchmark datasets of known binding
sites that can be used both to derive the appropriate
combination of features and to test the prediction
performance. So far, however, the availability of adequate
benchmarks has been a problem.
A number of binding sites datasets have been derived
from the PDB (8). But none combine enough of the
necessary attributes, namely to (i) be representative of
the known structural data, (ii) be non-redundant, (iii)
combine information on the apo- and holo-protein
structures, (iv) consist only of biologically relevant
binding sites, (v) take the description of the biological
unit of the protein into account, (vi) consider data from
all available holo-structures for each protein and lastly
(vii) be updated automatically.
Among the available datasets GOLD is a redundant set
of binding sites manually checked for structural errors
in the PDB ﬁles (9). SitesBase is a database of small
ligand-binding sites speciﬁcally designed to enable struc-
tural comparison of known ligand-binding sites (10). The
sc-PDB is a collection of binding sites speciﬁcally selected
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database attempts to annotate functional sites derived
from PDB SITE records and contact residues in hetero-
complexes (12). More recently, FireDB (13) has been
set-up to integrate data on binding sites from the PDB
and catalytic residues from the CSA (14), and organizes
these data so as to allow users to assess binding site
similarity in homologous proteins. To date, the only
dataset of ligand-binding sites explicitly restricted to
proteins with known apo-structures is the LIG dataset of
154 unique protein sequences that was used by
Najmanovich et al. (15). to analyse side-chain ﬂexibility
upon ligand-binding However, the LIG dataset has—to
our knowledge—not been maintained or updated, and
biologically irrelevant molecules are not consistently
excluded from it (with the exception of sulphate and
phosphate ions).
Here, we present LigASite (‘LIGand Attachment
SITE’), a dataset of ligand-binding sites in protein 3D
structures, which combines all of the seven attributes listed
above. In particular, it contains the description of
biologically relevant binding sites in proteins with at
least one apo- and one holo-structure. Information on the
apo-structure is key, since due to ligand-induced con-
formational changes, the structure of a protein without
and with the ligand (apo- and holo-structure, respectively)
can diﬀer (16,17). To mimic cases, where binding sites are
truly unknown, binding site prediction methods should be
validated by performing the predictions on apo-structures,
and comparing them with known binding sites deﬁned
from all corresponding holo-structures. Another common
problem when automatically deﬁning binding sites from
PDB holo-structures, is that some small molecules, which
appear in these entries may have been introduced as part
of the puriﬁcation and or crystallization procedure
and hence bind to the protein in a non-speciﬁc manner.
Although the corresponding binding sites are usually not
biologically relevant, some of these compounds may act as
inhibitors or substrate analogues and hence bind to
biologically relevant sites in the protein. With the aim of
identifying all biologically relevant binding sites, we deﬁne
them as sites bound by the biologically active ligands
identiﬁed in vivo or in vitro, as well as by any compound
that may act as inhibitor or substrate analogue. It is
admittedly not straightforward to distinguish between
such relevant ligands and non-speciﬁc binders. We
however show that protocols developed in LigASite
enable to automatically ﬁlter out non-speciﬁc binders
with a high degree of accuracy as determined by manual
validation (see Content and methods section). In all cases,
these protocols take into account the quaternary struc-
tures suggested by the PQS server (18). Using the correct
quaternary structures has an impact on the deﬁnition of
binding sites, as these can be located at the interface
between protein subunits. Optimal coverage and adequate
representation of the structural data available in the PDB
at any given time is enabled through fully automated
procedures, and no post-processing by the user is required.
LigASite is freely accessible at http://www.scmbb.
ulb.ac.be/Users/benoit/LigASite, and the data therein
can be downloaded as a set of Namespace-qualiﬁed
Schema-validated XML ﬁles.
CONTENT AND METHODS
The automated procedure used to generate the LigASite
dataset from the PDB is summarized in the ﬂowchart
of Figure 1.
Generalities
Binding sites in the LigASite dataset are exclusively
deﬁned on the basis of structural data from the PDB (8).
In constructing the dataset, the ﬁrst step involves selecting
Figure 1. Flow-chart summarizing the automated procedure to generate
LigASite from the PDB.
D668 Nucleic Acids Research, 2008, Vol. 36, Databaseissueall structures with at least one protein chain, using the
PDB search engine.
As a starting point, ligands are deﬁned as all non-water
molecules that appear in the HETATM records of PDB
entries. Such ligands are commonly referred to as ‘HET-
groups’. Binding sites for nucleic acids and other proteins
are hence ignored at this point. Quaternary structures
suggested by PQS (18) are used for all structures in the
dataset, unless PQS cannot be applied (e.g. NMR
structures). There are 27913 PDB entries with at least
one protein chain and at least one HET-group in the PDB
release of July 30, 2007, on which the current version of
LigASite is based. The total number of HET-groups in
these PDB entries amounts to 197860.
Selection ofbiologically relevant bindingsites
We deﬁne a binding site by the type of ligand that binds to
it. Biologically relevant binding sites are deﬁned as those
bound by the biologically active ligands identiﬁed in vivo
or in vitro, as well as by any compound that may act as
inhibitor or substrate analogue. Biologically irrelevant
sites are deﬁned as sites bound non-speciﬁcally by
compounds introduced by the puriﬁcation or crystal-
lization procedure.
In order to select biologically relevant sites, we ﬁlter out
ligands likely to be bound non-speciﬁcally. This is done
using a three-step procedure. First, HET-groups are
clustered together into HET-clusters when any of their
respective heavy atoms are located within <4.0A ˚ from
one another. This clustering is performed to account for
the fact that small solvent molecules often cluster together
in biologically relevant binding sites and mimic parts of
the natural ligand (e.g. phosphate or sulphate ions, which
mimic the phosphate groups of nucleotides). Individual
HET-clusters are treated here as single molecules. The
total of 197860 HET-groups in the PDB sums up to
148879 HET-clusters.
Second, HET-clusters with less than 10 heavy atoms are
rejected on the basis that biologically irrelevant molecules
in PDB ﬁles are generally very small. Since HET-clusters
are considered rather than single HET-groups, HET-
groups with less than 10 heavy atoms, such as phosphate
ions, can remain in the selected subset provided they are
part of a HET-cluster with a total of at least 10 heavy
atoms (e.g. two phosphate ions close to one another
are kept). Overall, 52246 HET-clusters contain at least
10 heavy atoms.
Finally, biologically relevant HET-clusters are selected
based on the number of inter-atomic protein–ligand
contacts. The underlying assumption being, that in
general, biologically relevant ligands interact speciﬁcally
with the proteins and should therefore make more inter-
atomic contacts with protein atoms than their irrelevant
counterparts. We use the program LPC (19) to compute
the inter-atomic contacts for the following reasons: it is
not restricted to a speciﬁc subset of bonds (e.g. hydrogen
bonds); it provides a detailed description of contacts based
on the physico-chemical properties of contacting atoms
and it is freely accessible and easy to run on a large
number of structures. To perform the selection based on
the above assumption, we deﬁne a threshold number of
inter-atomic contacts above, which an interaction is
guaranteed to be relevant. To that end, the number of
inter-atomic contacts between HET-cluster and protein is
calculated for all HET-clusters of the dataset. The dataset
is then divided into subsets based on ranges of 50 inter-
atomic contacts, as indicated in Table 1. For each range,
1% of the HET-cluster–protein binding sites have been
manually inspected to assess whether the binding site is
biologically relevant (this manual inspection was com-
pleted for an initial version of LigASite, which was based
on the December 22, 2006 PDB release). The 4th column
in Table 1 shows the fractions of binding sites that we
manually annotated as biologically relevant. As expected,
this fraction increases as the number of inter-atomic
contacts increases. Since the fraction of biologically
relevant binding sites steeply increases between the
ranges of 1–50 and 51–100 contacts, the subset of binding
sites having between 30 and 80 contacts was subdivided
into smaller bins of 10 inter-atomic contacts each, and
re-analysed. Results (Table 1) show that above 70 inter-
atomic contacts between HET-cluster and protein, the
HET-cluster is biologically relevant in at least 95% of
cases. The small number of cases where we manually
annotated the binding site as biologically irrelevant even
though it consists of at least 70 inter-atomic contacts
between protein and HET-cluster, all correspond to
membrane proteins in complex with membrane lipids,
which we were therefore able to readily exclude on the
basis of the ligand and/or protein type.
Table 1. Fractions of biologically relevant binding sites as a function of
the number of inter-atomic contacts between HET-cluster and protein,
for steps of 50 inter-atomic contacts and steps of 10 inter-atomic
contacts
No. of contacts






Steps of 50 inter-atomic contacts
1–50 6825 68 0.54
51–100 15326 153 0.93
101–150 9786 98 0.94
151–200 6531 65 0.98
>200 3932 39 0.98
Steps of 10 inter-atomic contacts
31–40 2145 21 0.10
41–50 2793 28 0.32
51–60 3287 33 0.64
61–70 3129 31 0.77
71–80 3293 33 0.97
The manual analysis summarised in this table was conducted using
an initial version of LigASite, which was based on the PDB release
of December 22, 2006.
aRange of number of inter-atomic contacts between protein and
HET-cluster.
bTotal number of binding sites where number of inter-atomic contacts
between protein and HET-cluster is within range given in column 1.
cNumber of binding sites inspected manually from the literature, used
for assessing biological relevance of HET-cluster. This number equals
1% of the number of sites in column 2.
dFraction of manually inspected binding sites that we annotated as
biologically relevant.
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HET-clusters that consist of at least 10 heavy atoms, and
that make at least 70 inter-atomic contacts with protein
atoms. There are 32656 such HET-clusters, consisting of
63105 individual HET-groups and distributed among
14459 PDB entries.
Selection of proteins withboth apo- and holo-structures
A gold-standard dataset of binding sites should include
information on both the apo- and holo-forms of the
protein, to enable taking into account the structural
changes that can occur in a protein upon binding of its
ligand(s).
In order to derive the list of ‘true’ apo-structures in the
PDB, we applied the following ﬁltering procedure. From
the PDB release of July 30, 2007, we selected all PDB
entries with at least one protein chain that is not in
complex with any other molecule, the latter being a small
molecule, another protein or a nucleic acid chain. This
procedure resulted in a set of 10046 PDB entries, which
was then ﬁltered to remove Ca-only and non-X-ray entries
and X-ray entries with resolution better or equal to 2.4A ˚ ,
and R-value better or equal to 0.25. These quality ﬁlters
were imposed to ensure that the apo-structures, which
should be used to apply functional site prediction
methods, are of suﬃcient quality to serve as input for
any type of methods including those that are based on
energy calculations (20). The ﬁnal set of high quality
apo-structures consist of 3995 PDB entries.
These apo-structures are then paired with the corre-
sponding holo-structures containing the biologically
relevant binding sites when they share 100% sequence
identity, thus resulting in a set of 550 entries with one apo-
structure and at least one holo-structure with a biologi-
cally relevant binding site. Removing redundancy at 25%
sequence identity [using PISCES (21)] results in
a non-redundant set of 286 proteins.
When several holo-structures are available for a given
protein, all are used to deﬁne its binding site. Many holo-
structures are bound to only a portion of the natural
ligands, and the picture of the binding site that is obtained
when considering all available holo-structures is therefore
more complete and accurate. Out of the 550 proteins in
the redundant dataset, 291 have more than one holo-
structure. A frequency score is assigned to all binding site
residues in a protein, based on the fraction of correspond-
ing holo-structures in which the residue is observed to be
part of a biologically relevant binding site (Figure 2).
Websiteimplementation
The fact that the construction of the dataset only relies on
simple numerical cut-oﬀs and automatic ﬁlters allows it to
be automatically updated as new data become available
in the PDB. At the time of writing the manuscript, the
current release of LigASite is based on the July 30, 2007
release of the PDB. LigASite is updated monthly.
LigASite is accessible at the following URL: http://
www.scmbb.ulb.ac.be/Users/benoit/LigASite. Both the
redundant and the non-redundant versions of the dataset
can be browsed. For each protein, a front-page describes
the apo-structure, and lists all binding site residues deﬁned
from the ensemble of corresponding holo-structures.
Binding site residue positions (i.e. PDB serial numbers)
are coloured on a yellow-to-red scale, depending on the
fraction of holo-structures in which the residue is found in
contact with a biologically relevant HET-cluster (red when
the fraction equals 1). Residue three-letter codes are
coloured according to their physico-chemical type. PDB
identiﬁers of corresponding holo-structures are listed
together with unique identiﬁers describing the biologically
relevant HET-clusters used to deﬁne the binding site
residues, the number of heavy atoms in the HET-clusters
and the number of inter-atomic contacts (identiﬁed with
LPC) between each HET-cluster and protein atoms.
A PDB ﬁle providing coordinates of the binding site
residues in the apo-structure can be downloaded for each
protein.
Clicking on the ‘Details’ links associated with holo-
structures leads to a holo-structure speciﬁc page, on which
more details can be found for each structure. Residues
identiﬁed as part of binding sites in the given holo-
structure are listed, together with the unique identiﬁer
Figure 2. Turkey egg-white lysozyme. (a) Mapping of binding site
residues on the apo-structure (PDB entry 135l). These residues are
identiﬁed as part of the binding site from the three holo-structures in
which the lysozyme is in complex with diﬀerent ligands: (b) with three
molecules of N-acetyl-D-glucosamine (NAG) and a sulphate ion in PDB
entry 1jef; (c) with di(N-acetyl-D-glucosamine) in PDB entry 1ljn; and
(d) with two molecules of NAG in PDB entry 1lzy. Binding site
residues are coloured red if they are in contact with ligand atoms in all
three holo-structures (i.e. frequency score of 1.0=3/3), they are
coloured orange if they are only in contact with ligand atoms in two
of the holo-structures (i.e. frequency score of 0.67 2/3), and they are
coloured yellow if they are in contact with ligand atoms in only one
holo-structure (i.e. frequency score of 0.33 1/3). HET-groups con-
sidered as biologically relevant in LigASite are displayed and coloured
in CPK. Sulphate ions ﬁltered out as biologically irrelevant in
PDB entry 1ljn are transparent and displayed in balls-and-sticks.
The ﬁgure was drawn with molscript (27) and rendered with
Raster3D (28).
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Residues interacting with HET-groups in other holo-
structures of the same protein are not listed. Further data
on the HET-groups that bind in biologically relevant
binding sites is also available from these pages, i.e. PDB
HET identiﬁers, molecule name, chemical formula and
(non-stereo) SMILES string. A PDB ﬁle providing
coordinates of the binding site residues and of the HET-
groups labelled as biologically relevant is available for
download for each holo-structure in the dataset.
Cross-links to relevant databases [e.g. PDBsum (22),
CSA (14)] are available on all pages, as well as links to
LIGPLOT (23) drawings of the interactions between
HET-groups and proteins. A search facility is available
and allows users to search LigASite for PDB identiﬁers
(both apo- and holo-), HET-group identiﬁers (e.g. ‘ATP’)
or protein names. The LigASite dataset can also be
searched by sequence similarity using BLAST (24). All
matches to a query sequence are returned to the user and
are sorted by sequence identity and E-value. Finally,
LigASite can be searched for proteins that have a domain
in the same CATH superfamily (i.e. H level) as the
domains in the PDB entry input by the user (25).
XML is a markup language that combines text and
information about this text. XML Schema allows to deﬁne
semantic constraints for the data contained in the XML
ﬁles. An XML ﬁle is not only humanly-readable, but
can also be easily parsed, and consequently validated
and transformed, by a computer. An XML Schema
(‘LigASiteML’) has been designed for a complete descrip-
tion of binding site information on the proteins of the
dataset. An XML ﬁle describing the complete LigASite
database is generated for each update, and validated
against the above-mentioned XML Schema. Both the
Schema and XML ﬁles are available for download from
the website, allowing users to easily use LigASite data
locally. In addition, protein-speciﬁc XML ﬁles, validated
against the same XML Schema, and describing only
binding site residues in a particular protein of the dataset
are available for download from the pages describing the
apo- and holo-structures of the corresponding protein.
A comma-separated ﬁle containing the core data of
LigASite, and created automatically from the XML ﬁle,
is also available for download.
Some Statistics on datasetcontent
The HET-groups featured in the biologically relevant
binding sites of LigASite proteins are very diverse. In
total, 551 diﬀerent HET-groups appear in the holo-
structures of the non-redundant LigASite dataset (redun-
dancy removed at 25% sequence identity). This number
exceeds the number of binding sites in the dataset because
(i) several diﬀerent HET-groups can appear together in a
binding site in a single holo-structure, e.g. a Magnesium
ion (HET ID ‘MG’) and a molecule of adenosine-50-
diphosphate (HET ID ‘ADP’) in the holo-structure 1pfk of
phosphofructokinase; and (ii) diﬀerent HET-groups can
appear in a given binding site in diﬀerent holo-structures
of a protein (Figure 2). The majority of HET-groups
appear in the binding site of only one protein, suggesting
an important diversity of ligands in the dataset.
Table 2 gives the names, HET IDs and numbers of
occurrences of the HET-groups that appear most fre-
quently in binding sites of the non-redundant version of
LigASite. When a HET-group appears in several holo-
structures of a given protein, only one occurrence is
counted. Therefore, the ‘number of occurrences’ in
this table corresponds to the number of diﬀerent proteins
to which a given HET-group binds. The most common
HET-group is the Magnesium ion, which occurs in the
binding sites of 41 diﬀerent proteins, as part of HET-
clusters consisting of more than 10 atoms (e.g. ‘MG’
together with ‘ATP’ constitute the HET-cluster in the
binding site of PDB entry 1e4g). Several nucleotides and
derivatives thereof are also among the most frequent
HET-groups in LigASite (i.e. ATP, ADP, AMP, GDP,
COA, NAD and NAP). Interestingly, a number of small
molecules commonly ignored in existing datasets of
binding sites because of their potential irrelevance,
appear in several binding sites in LigASite (i.e. phosphate
ions and glycerol molecules, and sulphate ions which
appear in the binding sites of six diﬀerent proteins).
We used the PDBSProtEC mapping (26), in order to
obtain the EC numbers for all 286 proteins in the non-
redundant version of LigASite, and for all the proteins of
a non-redundant version of the PDB [redundancy
removed at 25% sequence identity using PISCES (21)]
(Figure 3). Only 48 proteins out of 286 (i.e. 17%) in the
non-redundant version of LigASite are non-enzymes (26).
In the non-redundant version of the PDB, 39% of proteins
are non-enzymes. Among enzymes, transferases and
hydrolases (EC classes 2. and 3., respectively) are the
most common both in LigASite and the PDB.






Magnesium ion MG 41
Adenosine-50-diphosphate ADP 19










Coenzyme A COA 8




aHET-group name as provided in the PDB Chemical Component
Dictionary (see http://deposit.pdb.org/cc_dict_tut.html).
bHET-group ID (i.e. ‘residue name’ in PDB ﬁles).
cNumber of occurrences of HET-groups in LigASite (redundancy
removed at 25% seq. id.). When a given HET-group appears in several
diﬀerent holo-structures of a given protein, only one occurrence was
counted to compute values in this table.
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LigASite is a publicly available dataset of binding sites in
proteins with at least one known apo-structure and one
known holo-structure. Biologically irrelevant binding sites
are automatically ﬁltered out from the dataset with high
accuracy. The dataset relies on simple numerical cut-oﬀs
and is automatically updated regularly.
In its current version, LigASite contains binding sites
for all ligands stored as HET-groups in the PDB (e.g.
small organic compounds, oligo-saccharides, lipids,
nucleotides and derivatives thereof, etc.). We are presently
working on extending our protocol, in order to include
binding sites for peptides, proteins and nucleic acids.
We furthermore plan to derive an improved score for
excluding biologically irrelevant binding sites from the
dataset. This score, in which the number of inter-atomic
contacts between protein and ligand (i.e. the one currently
used) is normalized by the number of heavy atoms in the
ligand, should allow us to increase our coverage of the
small biologically relevant ligands, which make few
contacts with protein atoms (Table 1). We are also
working on the development of a structure-based search
facility to allow users to look for local structural matches
with binding sites in LigASite.
LigASite should prove a highly valuable resource for
validating and developing binding site prediction meth-
ods, and for the study of binding site properties in general.
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